Xuanzhu Biopharmaceutical (2575) Submits Filing for H Share Full Circulation to CSRC

Bulletin Express11-17

On November 17, 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) submitted a filing application to the China Securities Regulatory Commission (CSRC) to proceed with its proposed H Share Full Circulation plan. The proposal involves converting 357,245,794 unlisted shares into H shares on a one-for-one basis, pending completion of filing requirements and all necessary regulatory approvals.

According to the announcement, the conversion plan has not been finalized, and the company has yet to file an application with the Stock Exchange regarding the Conversion and Listing. Further details of the implementation plan and the final timeline will be disclosed subject to completion of relevant procedures, including approvals from the Stock Exchange and other authorities. The company has advised shareholders and potential investors to exercise caution when trading its shares until all steps are concluded.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138017233?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138017233","market":"hk","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical (2575) Submits Filing for H Share Full Circulation to CSRC","media":"Bulletin Express","content":"<p>On November 17, 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) submitted a filing application to the China Securities Regulatory Commission (CSRC) to proceed with its proposed H Share Full Circulation plan. The proposal involves converting 357,245,794 unlisted shares into H shares on a one-for-one basis, pending completion of filing requirements and all necessary regulatory approvals.</p>\n<p>According to the announcement, the conversion plan has not been finalized, and the company has yet to file an application with the Stock Exchange regarding the Conversion and Listing. Further details of the implementation plan and the final timeline will be disclosed subject to completion of relevant procedures, including approvals from the Stock Exchange and other authorities. The company has advised shareholders and potential investors to exercise caution when trading its shares until all steps are concluded.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical (2575) Submits Filing for H Share Full Circulation to CSRC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical (2575) Submits Filing for H Share Full Circulation to CSRC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-17 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On November 17, 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) submitted a filing application to the China Securities Regulatory Commission (CSRC) to proceed with its proposed H Share Full Circulation plan. The proposal involves converting 357,245,794 unlisted shares into H shares on a one-for-one basis, pending completion of filing requirements and all necessary regulatory approvals.</p>\n<p>According to the announcement, the conversion plan has not been finalized, and the company has yet to file an application with the Stock Exchange regarding the Conversion and Listing. Further details of the implementation plan and the final timeline will be disclosed subject to completion of relevant procedures, including approvals from the Stock Exchange and other authorities. The company has advised shareholders and potential investors to exercise caution when trading its shares until all steps are concluded.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1138017233","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138017233","pubTimestamp":1763369038,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On November 17, 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) submitted a filing application to the China Securities Regulatory Commission (CSRC) to proceed with its proposed H Share Full...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药(2575)向证监会提交H股全流通备案","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"On November 17, 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) submitted a filing application to the China Securities Regulatory Commission (CSRC) to proceed with its proposed H Share Full Circulation plan. The proposal involves converting 357,245,794 unlisted shares into H shares on a one-for-one basis, pending completion of filing requirements and all necessary regulatory approvals.\nAccording to the announcement, the conversion plan has not been finalized, and the company has yet to file an application with the Stock Exchange regarding the Conversion and Listing. Further details of the implementation plan and the final timeline will be disclosed subject to completion of relevant procedures, including approvals from the Stock Exchange and other authorities. The company has advised shareholders and potential investors to exercise caution when trading its shares until all steps are concluded.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138017233","isCrawlerRequest":true}